Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, Garber E, Browning J, Glaser SM.
Michaelson JS, et al.
MAbs. 2009 Mar-Apr;1(2):128-41. doi: 10.4161/mabs.1.2.7631. Epub 2009 Mar 11.
MAbs. 2009.
PMID: 20061822
Free PMC article.